Tagrisso plus chemo approved in U.S. for lung cancer
The FDA greenlit the Tagrisso/chemo regimen in treatment-naive EGFR-mutant NSCLC, bolstering AstraZeneca’s flagship brand against would-be rivals.
Source: mmm-online.com
Stay updated with breaking news from Merus Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA greenlit the Tagrisso/chemo regimen in treatment-naive EGFR-mutant NSCLC, bolstering AstraZeneca’s flagship brand against would-be rivals.